Mastura Md Yusof

Petaling Jaya, 46300, Malaysia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Guidelines for HER2 reporting in breast cancer: Recommendations by the Malaysian Breast Pathology Working Group.

Guidelines for HER2 reporting in breast cancer: Recommendations by the Malaysian Breast Pathology Working Group.

Journal: The Malaysian journal of pathology

Published: December 23, 2025

Outcomes in KEYNOTE-355 after chemotherapy discontinuation before pembrolizumab discontinuation and with immune-mediated adverse events.

Outcomes in KEYNOTE-355 after chemotherapy discontinuation before pembrolizumab discontinuation and with immune-mediated adverse events.

Journal: NPJ breast cancer

Published: December 15, 2025

Consensus Guidelines on Human Epidermal Growth Factor Receptor 2 (HER2)-Low Testing in Breast Cancer in Malaysia.

Consensus Guidelines on Human Epidermal Growth Factor Receptor 2 (HER2)-Low Testing in Breast Cancer in Malaysia.

Journal: Cancers

Published: May 28, 2024

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with early breast cancer.

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with early breast cancer.

Journal: ESMO open

Published: January 22, 2024

Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355.

Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355.

Journal: Journal of the National Cancer Institute

Published: July 12, 2023

Real-world multicenter study of the safety and efficacy of netupitant plus palonosetron fixed-dose combination to prevent chemotherapy-induced nausea and vomiting among Malaysian patients receiving moderately or highly emetogenic chemotherapy.

Real-world multicenter study of the safety and efficacy of netupitant plus palonosetron fixed-dose combination to prevent chemotherapy-induced nausea and vomiting among Malaysian patients receiving moderately or highly emetogenic chemotherapy.

Journal: Asia-Pacific journal of clinical oncology

Published: July 16, 2021

Oncologist-led BRCA counselling improves access to cancer genetic testing in middle-income Asian country, with no significant impact on psychosocial outcomes.

Oncologist-led BRCA counselling improves access to cancer genetic testing in middle-income Asian country, with no significant impact on psychosocial outcomes.

Journal: Journal of medical genetics

Published: September 08, 2020

Palbociclib and beyond for the treatment of HR + HER2- metastatic breast cancer: an Asian-Pacific perspective and practical management guide on the use of CDK4/6 inhibitors.

Palbociclib and beyond for the treatment of HR + HER2- metastatic breast cancer: an Asian-Pacific perspective and practical management guide on the use of CDK4/6 inhibitors.

Journal: Current medical research and opinion

Published: June 17, 2020

Prevalence and characteristics associated with default of treatment and follow-up in patients with cancer.

Prevalence and characteristics associated with default of treatment and follow-up in patients with cancer.

Journal: European journal of cancer care

Published: February 15, 2015

Discrepancy in patient-rated and oncologist-rated performance status on depression and anxiety in cancer: a prospective study protocol.

Discrepancy in patient-rated and oncologist-rated performance status on depression and anxiety in cancer: a prospective study protocol.

Journal: BMJ open

Published: October 05, 2012

Showing 1-10 of 10

Last Updated: 09/26/2026